Active — Not RecruitingNot Applicable

CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia Repairs

United States100 participantsStarted 2025-01-29

Plain-language summary

Pilot pragmatic trial using an implementation science approach to determine the feasibility of a CYP2D6-guided opioid prescribing for patients undergoing elective VHRs compared to usual care. Assess the efficacy (PROMIS Pain Intensity and Hernia-Related QOL) of a CYP2D6-guided opioid prescribing approach for patients undergoing elective VHRs.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \> 18 years age undergoing a ventral hernia repair (VHR) ≥1.5 cm in diameter with mesh. Exclusion Criteria: * ventral hernia \<1.5 cm * primary ventral hernia repair (VHR) without a mesh * emergency operative procedure * receiving chronic opioid therapy (defined as use of opioids on most days for \>3 months) * allergy to opioids * women of childbearing potential who have a positive pregnancy result as part of their standard pre-surgical workup

What they're measuring

Determine the feasibility of a CYP2D6-guided opioid prescribing by the percentage enrolled of patients undergoing elective VHRs compared to usual care.

Timeframe: 6 months

Trial details

NCT IDNCT06565546

SponsorUniversity of Florida

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-01

View on ClinicalTrials.gov More Ventral Hernia trials